A Phase 1 interventional study of AZD4144- Part A and Placebo- Part A in Healthy Participants, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
This is a Phase I, randomized study in healthy participants and consists of 3 parts; Part A, Part B and Part C. Part A and B are single-blind, placebo-controlled with single ascending dose (SAD) and multiple ascending dose (MAD) sequential group design, respectively. Part C is an open-label, 2-period, 2-sequence, cross-over design study. Part A and B of the study will assess the safety, tolerability, PK, and PD of AZD4144 solution for infusion compared with placebo while Part C will investigate the possibility of DDI between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
The study will comprise of:
A residential period which lasts from,
A final follow-up visit,
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive one single ascending dose of AZD4144.
Drug: AZD4144- Part A
Participants will receive multiple ascending doses of AZD4144.
Drug: AZD4144- Part B
Participants will receive multiple ascending doses of AZD4144.
Drug: AZD4144- Part B
Participants will receive multiple ascending doses of AZD4144.
Drug: AZD4144- Part B
Participants will receive multiple ascending doses of AZD4144.
Drug: AZD4144- Part B
Participants will receive rosuvastatin and furosemide.
Drug: Rosuvastatin and Furosemide- Part C
Participants will receive rosuvastatin, furosemide, and AZD4144.
Drug: Rosuvastatin, Furosemide, and AZD4144 Part C
Participants will receive matching placebo.
Drug: Placebo- Part A
Participants will receive matching placebo.
Drug: Placebo- Part A
Participants will receive matching Placebo.
Drug: Placebo- Part A
Participants will receive matching Placebo.
Drug: Placebo- Part B
Participants will receive matching Placebo.
Drug: Placebo- Part B
Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.
Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.
Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion. Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.
Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.
Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.
Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
Number of participants with adverse events (AEs) (Part A and Part B)
To assess the safety and tolerability of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses in healthy participants.
Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3.
Area under plasma concentration-time curve from time 0 to infinity (AUCinf) (Part C)
To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.
Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) (Part C)
To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.
Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Maximum observed drug concentration (Cmax) (Part C)
To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.
Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Cmax (Part A and Part B)
To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses.
Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3
AUClast (Part A and Part B)
To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses
Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3
AUCinf (Part A)
To characterize the PK of AZD4144 following IV administration of single (Part A) ascending doses.
Time frame: Part A: Day 1 to Day 10+3
Area under concentration-time curve in the dosing interval (AUCτ) (Part B only)
To characterize the PK of AZD4144 following IV administration of multiple (Part B) ascending doses
Time frame: Part B: Day 1 to Day 20+3
Renal clearance of drug from plasma (CLR) (Part A and Part B)
To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses.
Time frame: Part A: Day 1 to 3; Part B: Day 1, 12 and 20+3
PD analysis: Levels of disease-specific biomarkers (Part A and Part B)
To assess the effect of AZD4144 on levels of disease-specific biomarkers. (Part A and Part B)
Time frame: Part A: Day -1 to 4; Part B: Day -1 to Day 1, Day 12 to Day 15
Number of participants with adverse events (AEs) (Part C)
To assess the safety and tolerability of AZD4144 in combination with rosuvastatin and furosemide in healthy participants.
Time frame: Part C: Day 1 to Day 20+3
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Jun 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD4144